What is GHRP-6?
GHRP-6 is a growth-hormone secretagogue with effects extending beyond a single hormone. Human physiology studies help explain that distinction.
Biological role or research focus
Growth-hormone release.
A response in growth hormone is not itself a demonstrated recovery or performance outcome.
Role reference: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗
Names you may encounter
GHRP 6 · GHRP6
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Synthetic growth-hormone-releasing peptide
- Main research area
- Endocrine and sleep physiology
- Evidence featured
- Human physiology experiment
- Source check
- October 4, 2026
Quick answers
- Is GHRP-6 FDA approved?
- No. No FDA-approved drug contains GHRP-6. FDA lists it in 503A category 3: nominated for compounding without enough supporting information. Source ↗
- Is GHRP-6 safe?
- GHRP-6 is an unapproved growth-hormone secretagogue. Short human studies show it also raises cortisol and ACTH, and FDA cites possible blood-sugar effects and immune-reaction risk. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is GHRP-6 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
- Has the FDA taken action over GHRP-6?
- Yes. Our records list 1 FDA action naming it, most recently on April 1, 2020: FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing GHRP-6 among bulk substances that are not eligible for 503A compounding exemptions. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Sleep and hormone experiment (1995) | Human physiology experiment | Healthy male volunteers. |
| GHRP-6 · diagnostic GH responses (1996) | Human diagnostic study | Short-statured children and adults assessed for growth-hormone deficiency; participant counts are not supplied in the abstract. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human physiology experiment · 1995
Sleep and hormone experiment
Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.
- Population / model
- Healthy male volunteers.
- Study design
- Repeated GHRP-6 or placebo administration with overnight hormone sampling and sleep EEG.
- Main finding
- Growth hormone, ACTH, and cortisol increased. Stage-2 sleep increased; slow-wave sleep did not.
- Limits & context
- The response was not restricted to growth hormone. An overnight physiology study does not establish treatment for chronic insomnia, injury recovery, or long-term athletic performance.
Human diagnostic study · 1996
GHRP-6 · diagnostic GH responses
Can a hormone response distinguish growth-hormone deficiency?
- Population / model
- Short-statured children and adults assessed for growth-hormone deficiency; participant counts are not supplied in the abstract.
- Study design
- Hormone-response comparisons after GHRP-6, including combined GHRH testing in selected groups.
- Main finding
- Average responses were lower in deficient patients, but individual results overlapped substantially with controls. Markedly reduced responses were reported with pituitary stalk transection.
- How to read it
- Different group averages do not automatically make a reliable individual diagnostic test.
- Limits & context
- Incomplete diagnostic-performance reporting prevents assessing sensitivity or specificity. A transient hormone response is not evidence of muscle gain, injury recovery, or a safe self-treatment regimen.
Source: Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming GHRP-6 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 3 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. ↗
International heart journal · 2017 Apr 6 · Journal Article
N-aminoimidazolidin-2-one peptidomimetics. ↗
Organic letters · 2014 Apr 18 · Journal Article, Research Support, Non-U.S. Gov't
Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. ↗
Journal of nanobiotechnology · 2025 Dec 1 · Journal Article
Read available full text ↗
Risks & interactions
GHRP-6 is an unapproved growth-hormone secretagogue. Short human studies show it also raises cortisol and ACTH, and FDA cites possible blood-sugar effects and immune-reaction risk.
Human data come from small, short physiology and diagnostic studies. Long-term safety, including effects on blood sugar and stress hormones with repeated use, has not been studied.
Unassessed: little human safety data
Take extra care with: Diabetes or blood-sugar medicines
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Interactions
- Diabetes: may raise blood glucose by reducing insulin sensitivity (FDA)
Serious risks
- FDA: possible rise in blood glucose from reduced insulin sensitivity
- Raises the stress hormones cortisol and ACTH, not only growth hormone (human study)
- FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · GHRP-6 stimulates sleep, GH, ACTH and cortisol in men (1995) ↗ · GHRP-6 test in the diagnosis of GH deficiency (1996) ↗ · Safety and efficacy of growth hormone secretagogues (review, 2018) ↗
Safety evidence & remaining uncertainty
The experiment’s broader endocrine response is relevant to safety interpretation. Its short duration cannot resolve effects of prolonged exposure or use with other hormone-active substances.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 3 (nominated without enough support)
Listed in 503A category 3 ("GHRP-6", nominated without adequate support). Separately, FDA placed GHRP-6 in 503B category 2 (significant safety risks) on September 29, 2023. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly ("GHRP-6"). source
FDA actions
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing GHRP-6 among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Other notes
- FDA lists GHRP-6 in 503B category 2 for outsourcing facilities, citing immunogenicity risk and effects on cortisol and blood glucose. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
Research into overnight hormone patterns and sleep stages does not establish a treatment for insomnia, muscle loss, or injury recovery.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
The cited experiment found growth-hormone release alongside activation of ACTH and cortisol secretion. It therefore should not be described as an exclusively growth-hormone-specific signal.
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- A response in growth hormone is not itself a demonstrated recovery or performance outcome.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did it increase deep slow-wave sleep in this study?
No. Stage-2 sleep increased while slow-wave sleep did not.
Are GHRP-6 and GHRH the same substance?
No. They can both stimulate growth-hormone release, but their endocrine responses differed in this comparison.
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Animal comparator data · PMID 9849822 ↗
- Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗
- Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
